One year later: The case of tocilizumab in COVID-19-Reference-Cited by-同舟云学术

One year later: The case of tocilizumab in COVID-19

Published:2022-01 Issue: Volume:95 Page:5-6
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

Campochiaro Corrado,Tomelleri Alessandro,Matucci-Cerinic Marco,Dagna Lorenzo

Publisher

Elsevier BV

Subject

Internal Medicine

Reference20 articles.

1. COVID-19: consider cytokine storm syndromes and immunosuppression;Metha;Lancet,2020

2. Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies;Bonaventura;Front Immunol,2020

3. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China;Ruan;Intensive Care Med,2020

4. The conundrum of interleukin-6 blockade in COVID-19;Campochiaro;Lancet Rheumatol,2020

5. Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: a comprehensive review of available and emerging evidence at the peak of the pandemic;Cavalli;Front Pharmacol,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune regulators for the treatment of COVID-19: A critical appraisal after two years;European Journal of Internal Medicine;2023-10

2. Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy;Cells;2023-06-19

3. Efficacy of Tocilizumab in Severely Ill COVID-19 Patients With Rapid Respiratory Deterioration: A Single Center Experience During the Third Pandemic Wave in Greece;In Vivo;2023

4. Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants;Journal of Personalized Medicine;2022-07-04

5. Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19;European Journal of Internal Medicine;2022-06